CNR2 and prostate carcinoma: Quantification of LDH release showed that under the conditions employed, 24 h treatment of DU-145 cells with docetaxel (500 nM; a standard chemotherapeutic drug used to treat prostate cancer), the CB1-selective antagonist/inverse agonist rimonabant (50 μM), and the CB2-selective agonist GW-405833 (50 μM) resulted in significant increases in LDH release of 16.8 ± 3.4, 16.5 ± 3.5 and 74.2 ± 4.5%, respectively, compared to vehicle-treated cells (control) (Figure 7A).